Jefferies Cuts Price Target on DaVita (DVA) to $70; Reiterates Buy

November 16, 2016 8:12 AM EST
Get Alerts DVA Hot Sheet
Price: $62.90 -1.55%

Rating Summary:
    7 Buy, 11 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade DVA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies maintained a Buy rating on DaVita (NYSE: DVA), and cut the price target to $70.00 (from $86.00), as Obamacare uncertainty creates risk.

Analyst Chris Cooper commented, "Regulatory concerns restrict valuation but core dialysis is robust (3 Qs of share gains). DVA stepped away from ACA premium assistance for 2k Medicaid patients (1.1% of its total), removing the majority of repeal risk, although the path for 3k ACA patients (otherwise uninsured) is less certain. Our bear case (-$230m EBIT; $500m 'steering' fine) offers 3% upside from current levels; we see strong asymmetric upside risk. DVA trades on 16.0x 2017 P/E for 12% CAGR."

For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.

Shares of DaVita closed at $60.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment